; and (B) by striking 2024 and inserting 2029 . (d) Fee waiver or reduction; exemption from fees Subsection (d) of section 741 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21 ) is amended to read as follows: (d) Fee waiver or reduction The Secretary shall grant a waiver from, or a reduction of, one or more fees assessed under subsection (a) where the Secretary finds that the generic new animal drug is intended solely to provide for a minor use or minor species indication. . (e) Effect of failure To pay fees Section 741(e) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21(e) ) is amended by striking The Secretary may discontinue and inserting A request to establish a generic investigational new animal drug file that is submitted by a person subject to fees under subsection (a) shall be considered incomplete and shall not be accepted for action by the Secretary until all fees owed by such person have been paid. The Secretary may discontinue . (f) Assessment of fees Section 741(f)(2) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21(f)(2) ) is amended by striking sponsors, and generic new animal drug products at any time and inserting products, generic new animal drug sponsors, and generic investigational new animal drug files at any time . (g) Crediting and availability of fees Section 741(g) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21(g) ) is amended— (1) in paragraph (3), by striking 2019 through 2023 and inserting 2024 through 2028 ; (2) by striking the second paragraph (4) (relating to Offset), as added by section 202 of the Animal Generic Drug User Fee Amendments of 2013 ( Public Law 113–14 )